Mustang Bio Inc

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. Its pipeline includes MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy in Phase I trials for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination of MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program that completed Phase I for glioblastoma; and MB-108, in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. The company has license agreements with City of Hope National Medical Center and Nationwide Children's Hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.